From Financial Modeling Prep: 2025-03-24 07:00:00

In the biopharmaceutical industry, MannKind Corporation (NASDAQ:MNKD) is showing positive capital efficiency with a ROIC to WACC ratio of 1.69, indicating effective capital utilization. Competitors like ACADIA Pharmaceuticals lead with a ratio of 4.22, while Geron Corporation and Celldex Therapeutics struggle with negative ratios, reflecting challenges in generating sufficient returns. Exelixis also demonstrates positive capital efficiency, though not as high as ACADIA.



Read more at Financial Modeling Prep:: MannKind Corporation’s Capital Efficiency Stands O…